Vasant Prakash Gandhi

Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA.

Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation

Avesthagen Ltd. provides personalized healthcare through convergence of food, pharma and population genetics. It offers genome analysis, transcriptome analysis, metabolome analysis and lead optimization, and recombinant protein expression services, as well as engages in the generation of stable mammalian cell lines over-expressing a recombinant protein, development of product specific bioassays, and design of novel animal component free production media. The company was founded by Villoo Morwala Zareer Patell on April 20, 1998 and is headquartered in Bangalore, India.

ApoVax, Inc. developed immunotherapies and therapeutic vaccines. It was a biotechnology company that developed novel immunotherapies, which are treatments based on regulating the host immune system to fight disease. The firm was a scientific foundation that built on two platform technologies that are used to modulate the immune system-ProtEx and ApoVax. The company was founded by Haval Shirwan in 2001 and was headquartered in Louisville, KY.